.png)
At Edison, our goal is to use AI to accelerate the entire pipeline of new medicines, from basic discovery to clinical development. Drug development is fundamentally cumulative: every experiment, analysis, and clinical outcome generates information that should improve future decisions. Yet today, most of that knowledge remains fragmented across teams, systems, and stages of the R&D process.
We believe the full gains from scientific AI will only be realized when AI systems are integrated across the entire research and development stack, continuously learning from the evolving scientific context inside an organization.
Building AI-native biopharma organizations will require AI systems that participate directly in scientific workflows, decision-making, and organizational learning.
Building AI-Native Biopharma Organizations
Today, we are delighted to announce a partnership with Incyte Corporation (NASDAQ:INCY) to pioneer a new model for AI-enabled drug discovery and development.
Kosmos will be embedded across the Incyte discovery and development lifecycle, enabling continuous learning from translational and clinical data, real-time synthesis of evidence and predictive models of therapeutic performance.
Our initial deployment with Incyte will focus on integrating Kosmos into high-impact workflows in target discovery, target validation, and translational biology. By embedding our platform directly into Incyte’s research environment, we aim to help Incyte's researchers more effectively synthesize experimental, clinical, and biomarker data, generate and evaluate hypotheses, and support critical R&D decisions throughout the development process. Over time, we expect these capabilities to expand across Incyte’s broader R&D organization.
Kosmos: The AI Scientist for R&D
To meet the needs of Incyte and future biopharma partners, we have rearchitected Kosmos to cover the full biopharma R&D lifecycle, from discovery to development.
We have made a number of improvements to Kosmos, aimed at making it more interactive, more powerful, and more useful for scientists throughout the pharma R&D stack. These changes will help scientists and researchers ask better questions, produce better study designs, and increase confidence around go and no-go calls.
You can apply for access to the new Kosmos here. We will work on expanding access as capacity becomes available.
The new Kosmos introduces several major advancements for biopharma R&D:
- Built for and validated across clinical development: To extend Kosmos into clinical development, we introduced new data sources, skills, and reasoning models spanning toxicology, clinical trials, and regulatory documentation. We have validated Kosmos by reproducing key stages of clinical development for a novel checkpoint inhibitor, from lead identification through a Phase II proof-of-concept study.
- A persistent scientific collaborator: Because scientific reasoning is inherently iterative, we rebuilt the experience of working with Kosmos around a persistent, synchronous interface on top of our native asynchronous agent architecture. Kosmos can now interact with researchers and take feedback from them as it goes about its work, making it much easier and more natural for researchers to collaborate with Kosmos on producing complex outputs. Researchers can chat with Kosmos in real time, receive updates as investigations progress, and collaborate with Kosmos through shared workflows, including Slack, Teams and email. Kosmos can also provision compute for GPU-intensive tasks such as AlphaFold and molecular docking calculations, author PDFs, and interpret figures from recent scientific papers.
- Trained on your organization’s data: Kosmos now integrates with local datasets, cloud storage, and warehouse systems including ELNs, assay data, biomarker data, and unstructured scientific notes, enabling researchers to reason across proprietary organizational knowledge throughout the R&D pipeline.
- Leveraging scientific world models: Kosmos constructs internal scientific world models that integrate literature, experiments, clinical outcomes, and organizational context across discovery and development.
- Natively trainable architecture: The models underlying Kosmos can now be trained directly with reinforcement learning and supervised fine-tuning on experimental and reasoning data provided by our partners, helping those partners to build a sustainable intelligence advantage.
- Enterprise-grade security and traceability: Built for enterprise deployment with SOC 2 compliant infrastructure and fully auditable workflows, Kosmos enables researchers to trace analyses, reasoning steps, and scientific decisions across complex investigations.
How Individual Academics and Researchers Can Continue to Work with Kosmos
The academic and grass-roots research community played an important role in shaping Kosmos, and we remain committed to supporting researchers working at the frontier of science. Many of the capabilities announced today were informed directly by how researchers used Kosmos in practice, and we intend to continue working closely with the academic community as the platform evolves.
Here is what that looks like now:
- Our core research agents will remain publicly available through the Edison Playground. This includes our Literature agent (formerly Crow), our Analysis agent (formerly Finch), and our Precedent agent (formerly HasAnyone/Owl). All users will continue to have 10 free credits per month for those agents. The legacy Kosmos interface will also be available there for a limited time.
- Our free tier for academics is changing. Academics who previously received 650 credits/month will now receive a one-time block grant of 2000 credits instead of monthly refreshers. These credits can be used on the Edison Playground. We will launch an updated free tier for academics in a few months.
- We will shortly introduce new Kosmos subscriptions. Founding Kosmos subscriptions will no longer be available. We plan to announce new subscriptions in the coming months. To thank all of our existing subscribers for their support, existing subscribers will receive priority access to Kosmos with significantly higher rate limits and heavily discounted access to higher-tier plans at the same price in the future.
You can apply for access to the new Kosmos here. We will work on expanding access as capacity becomes available.
